United Therapeutics is a biotechnology company. Co. markets and sells four commercial therapies in the U.S. to treat pulmonary arterial hypertension: Tyvaso® (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin® (treprostinil) Injection (Remodulin); Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, which is approved for treatment of high-risk neuroblastoma, and the Remunity® Pump for Remodulin.
UTHR — Key Stats (updated Friday, March 31, 10:28 AM)